Bioxyne lands $50m exclusive German supply deal with ADREXpharma, securing $25m minimum in first year, boosting Europe revenue visibility and 12-month renewal.
Key points
- Secured $50M exclusive German supply deal with ADREX, including $25M minimum commitment.
- Bolsters European market presence, leveraging Germany’s position as the largest medicinal cannabis market.
- Builds on existing international contracts and capacity expansion, but execution risks remain.
Bioxyne (ASX: BXN) has secured a significant $50 million exclusive German supply agreement with ADREXpharma, marking a substantial expansion into Europe’s largest medicinal cannabis market.
The deal, which includes a $25 million minimum commitment in the first year, bolsters near-term revenue visibility and extends the company’s international reach.
The contract, signed by Bioxyne subsidiary Breathe Life Sciences, also features an automatic 12-month renewal for the agreement.
This latest agreement expands on an initial supply agreement executed with ADREX in June 2025. It reflects increasing demand for Breathe Life Sciences’ GMP-certified products across Europe.
Article by Small Caps | read more: https://smallcaps.com.au/article/bioxyne-secures-50m-exclusive-german-supply-deal-with-adrex